Por favor, use este identificador para citar o enlazar este Item:http://hdl.handle.net/20.500.12105/16083
Título
Longer intervals between SARS-CoV-2 infection and mRNA-1273 doses improve the neutralization of different variants of concern
Autor(es)
García-Pérez, Javier ISCIII | Bermejo, Mercedes ISCIII | Ramírez-García, Almudena | de la Torre-Tarazona, Humberto Erick ISCIII | Cascajero Díaz, Almudena ISCIII | Castillo de la Osa, María ISCIII | Jiménez Santana, Paloma ISCIII | Aparicio Gómez, Marta | Calonge, Esther ISCIII | Sancho-López, Aránzazu | Payares-Herrera, Concepción | Layunta Acero, Rocio | Vicente-Izquierdo, Laura | Avendaño-Solá, Cristina | Alcamí, José ISCIII | Perez-Olmeda, Mayte ISCIII | Díez-Fuertes, Francisco ISCIII
Fecha de publicación
2023-03
Cita
J Med Virol. 2023 Mar;95(3):e28679.
Idioma
Inglés
Tipo de documento
research article
Resumen
The humoral immune response against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern elicited by vaccination was evaluated in COVID-19 recovered individuals (Rec) separated 1-3 months (Rec2m) or 4-12 months (Rec9m) postinfection and compared to the response in naïve participants. Antibody-mediated immune responses were assessed in 66 participants by three commercial immunoassays and a SARS-CoV-2 lentiviral-based pseudovirus neutralization assay. Immunoglobulin (Ig) levels against SARS-CoV-2 spike were lower in naïve participants after two doses than in Rec after a single dose (p < 0.05). After two doses in Rec, levels of total Ig to receptor-binding domain were significantly increased in Rec9m compared to Rec2m (p < 0.001). The neutralizing potency observed in Rec9m was consistently higher than in Rec2m against variants of concern (VOCs) Alpha, Beta, Delta, and BA.1 sublineage of Omicron with 2.2-2.8-fold increases. Increasing the interval between SARS-CoV-2 infection and the vaccination with messenger RNA-based vaccines to more than 3 months generates a more efficient heterologous humoral immune response against VOCs by allowing enough time to mount a strong recall memory B cell response.
Palabras clave
MESH
COVID-19 | Humans | 2019-nCoV Vaccine mRNA-1273 | SARS-CoV-2 | mRNA Vaccines | Biological Assay | Vaccination | Antibodies, Neutralizing | Antibodies, Viral | Spike Glycoprotein, Coronavirus
Versión en línea
DOI
Aparece en las colecciones